

# CITATION REPORT

List of articles citing

## Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know

DOI: 10.7326/m20-1334

Annals of Internal Medicine, 2020, 172, 754-755.

**Source:** <https://exaly.com/paper-pdf/75749835/citation-report.pdf>

**Version:** 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
162	Oxidative Stress, Proton Fluxes, and Chloroquine/Hydroxychloroquine Treatment for COVID-19. <b>2020</b> , 9,		9
161	Potential Therapeutic Options for COVID-19. <b>2020</b> , 2, 89-95		
160	Ethics and Economics of the COVID-19 Pandemic in the United States. <b>2020</b> , 7, 2333392820957661		2
159	Coronavirus Disease 2019 (COVID-19) as a Multi-Systemic Disease and its Impact in Low- and Middle-Income Countries (LMICs). <b>2020</b> , 2, 1-11		27
158	The impact of COVID-19 on research. <b>2020</b> , 16, 715-716		31
157	COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus. <b>2020</b> , 203, 112647		17
156	COVID-19: Impacts and Implications for Pediatric Practice. <b>2020</b> , 34, 619-629		6
155	The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics. <b>2020</b> , 257, 118097		36
154	Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making. <b>2020</b> , 46, 574-578		8
153	Opportunities for biomaterials to address the challenges of COVID-19. <b>2020</b> , 108, 1974-1990		30
152	Biomedical Research in Times of Emergency: Lessons From History. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, 297-299	8	8
151	Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment?-The IDENTIFY Trial. <b>2020</b> , 9,		6
150	Antiviral drugs and plasma therapy used for Covid-19 treatment: a nationwide Turkish algorithm. <b>2020</b> , 52, 531-539		
149	COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. <b>2020</b> , 37, 100738		49
148	Sex-related differences in COVID-19 lethality. <b>2020</b> , 177, 4375-4385		36
147	A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic. <b>2020</b> , 2, 491-495		3
146	Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review. <b>2020</b> , 39, 2803-2810		26

145	Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection. <b>2020</b> , 28, 745-764	9
144	SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) - A drug repurposing study. <b>2020</b> , 6, e04502	45
143	Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: A pilot study. <b>2020</b> , 60, 328-333	25
142	"Tomorrow Never Dies": Recent Advances in Diagnosis, Treatment, and Prevention Modalities against Coronavirus (COVID-19) amid Controversies. <b>2020</b> , 8,	12
141	The prospective influence of COVID-19 affective risk assessments and intolerance of uncertainty on later dimensions of health anxiety. <b>2020</b> , 75, 102290	34
140	Response to: 'Correspondence on ': hydroxychloroquine, COVID-19 and the role of the rheumatologist' by Graef ' by Lo. <b>2020</b> ,	1
139	Recent Advances in Pathophysiology, Drug Development and Future Perspectives of SARS-CoV-2. <b>2020</b> , 8, 580202	19
138	Hydroxychloroquine and Chloroquine in COVID-19: A Survey of Prescription Patterns Among Rheumatologists. <b>2020</b> , 26, 224-228	3
137	Risk factors of non-adherence to guidelines for the prevention of COVID-19 among young adults with asthma in a region with a high risk of a COVID-19 outbreak. <b>2021</b> , 58, 1630-1636	9
136	Digital crowdsourcing: unleashing its power in rheumatology. <b>2020</b> , 79, 1139-1140	8
135	Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. <b>2020</b> , 2, e689-e697	29
134	Medicare expenditures for conventional and biologic disease modifying agents commonly used for treatment of rheumatoid arthritis. <b>2020</b> , 50, 822-826	2
133	COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020. <b>2020</b> , 26, 2513-2515	7
132	Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection. <b>2020</b> , 57, 4856-4877	20
131	COVID-19 and African rheumatology: progress in adversity. <b>2020</b> , 2, e732-e734	2
130	Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). <b>2020</b> , 251, 228-248	473
129	The Parallel Pandemic: Medical Misinformation and COVID-19 : Primum non nocere. <b>2020</b> , 35, 2435-2436	18
128	Natural experiment concept to accelerate the Re-purposing of existing therapeutics for Covid-19. <b>2020</b> , 2, 100026	4

127	Hydroxychloroquine hitting the headlines-retinal considerations. <b>2020</b> , 34, 1158-1160		5
126	SARS-CoV-2 infection among patients with systemic autoimmune diseases. <b>2020</b> , 19, 102575		97
125	Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. <b>2020</b> , 9,		285
124	Gaucher disease and SARS-CoV-2 infection: Emerging management challenges. <b>2020</b> , 130, 164-169		14
123	Impact of COVID-19 pandemic on SLE: beyond the risk of infection. <b>2020</b> , 7,		19
122	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. <b>2020</b> , 190, 346-357		8
121	Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating COVID-19. <b>2020</b> , 17, 1445-1451		17
120	Hydroxychloroquine for Coronavirus: The Urgent Need for a Moratorium on Prescriptions. <b>2020</b> , 133, 1007-1008		1
119	Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. <i>BMJ, The</i> , <b>2020</b> , 369, m1844	5.9	266
118	Prescribing COVID-19 treatments: what we should never forget. <b>2020</b> , 81, e85		2
117	A chronicle of SARS-CoV-2: Part-I - Epidemiology, diagnosis, prognosis, transmission and treatment. <i>Science of the Total Environment</i> , <b>2020</b> , 734, 139278	10.2	58
116	Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days. <b>2020</b> , 33, e13686		6
115	Navigating COVID-19 in the developing world. <b>2020</b> , 39, 2039-2042		4
114	COVID-19 (SARS-CoV-2 Infection) and Children: Pediatric Neurologist's Perspective. <b>2020</b> , 87, 556-557		15
113	Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor. <b>2020</b> , 31, 179-193		79
112	Arthroplasty during the COVID-19 Pandemic. <b>2020</b> , 6, 427-430		7
111	Targeting SARS-CoV-2 receptors as a means for reducing infectivity and improving antiviral and immune response: an algorithm-based method for overcoming resistance to antiviral agents. <b>2020</b> , 9, 1397-1406		31
110	Probiotics and COVID-19: is there any link?. <b>2020</b> , 71, 229-234		49

109	COVID-19 research: an opinion piece. <b>2020</b> , 21, 536-540	3
108	Compassionate Use of Hydroxychloroquine in Clinical Practice for Patients With Mild to Severe COVID-19 in a French University Hospital. <b>2021</b> , 73, e4064-e4072	34
107	Response to: Broadbent 2020, Better the drug you know: Commentary on "Daughton 2020, Natural experiment concept to accelerate the re-purposing of existing therapeutics for Covid-19". <b>2020</b> , 2, 100028	
106	Coronavirus disease 2019 (COVID-19): an evidence map of medical literature. <b>2020</b> , 20, 177	42
105	Chloroquine: A Potential Drug in the COVID-19 Scenario. <b>2020</b> , 5, 399-410	7
104	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. <b>2020</b> , 16, 659-666	40
103	Internet Searches for Unproven COVID-19 Therapies in the United States. <b>2020</b> , 180, 1116-1118	53
102	Rethinking the role of hydroxychloroquine in the treatment of COVID-19. <b>2020</b> , 34, 6027-6037	82
101	Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. <b>2020</b> , 5, 1067-1069	174
100	Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals. <b>2020</b> , 25, 956-958	3
99	Early impact of COVID-19 on transplant center practices and policies in the United States. <b>2020</b> , 20, 1809-1818	161
98	Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the COVID-19 Pandemic. <b>2020</b> , 2, 335-343	85
97	SLE patients are not immune to covid-19: importance of sending the right message across. <b>2021</b> , 80, e23	9
96	10 "C" in COVID19. <b>2020</b> , 14, 93	
95	An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e13825	2.9 5
94	Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead. <b>2021</b> , 890, 173717	14
93	Hydroxychloroquine for Prevention of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: Challenges to Trial Conduct During the Global Pandemic. <b>2021</b> , 72, e844-e847	2
92	Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study. <b>2021</b> , 82, 86-96	28

91	Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection. <b>2021</b> , 36, 115-120	11
90	Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic. <b>2021</b> , 87, 1758-1767	4
89	An overview of viruses discovered over the last decades and drug development for the current pandemic. <b>2021</b> , 890, 173746	3
88	Repurposing medications. <b>2021</b> , 19, 336-340	4
87	A First Draft of the History of Treating Coronavirus Disease 2019: Use of Repurposed Medications in United States Hospitals. <b>2021</b> , 8, ofaa617	1
86	A Revisit to the Research Updates of Drugs, Vaccines, and Bioinformatics Approaches in Combating COVID-19 Pandemic. <b>2020</b> , 7, 585899	6
85	COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. <b>2021</b> , 232, 13-36	26
84	Exploring the Mental Health Needs of Persons With Autoimmune Diseases During the Coronavirus Disease 2019 Pandemic: A Proposed Framework for Future Research and Clinical Care. <b>2021</b> , 3, 25-33	0
83	Access to data from clinical trials in the COVID-19 crisis: open, flexible, and time-sensitive. <b>2021</b> , 130, 143-146	10
82	Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. <b>2021</b> , 893, 173813	14
81	Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses. <b>2021</b> , 19, 1-15	11
80	COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics. <b>2021</b> , 49, 199-213	46
79	In silico prediction of new mutations that can improve the binding abilities between 2019-nCoV coronavirus and human ACE2. <b>2021</b> , PP,	1
78	The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. <b>2021</b> , 17, 177-184	12
77	Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. <b>2021</b> , 166, 949-954	65
76	Topological Study of Hydroxychloroquine Conjugated Molecular Structure Used for Novel Coronavirus (COVID-19) Treatment. 1-17	8
75	COVID-19 illness and autoimmune diseases: recent insights. <b>2021</b> , 70, 407-428	5
74	COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review. <b>2021</b> , 203, 2043-2057	4

73	Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?. <b>2021</b> , 35, 101658		2
72	Photodynamic Therapy: A Rational Approach Toward COVID-19 Management. <b>2021</b> , 000, 000-000		1
71	Nursing Leadership in COVID-19 EducationChronologic Indexing of Information and Assurance of Receipt of Information. <b>2021</b> , 13, 91-95		
70	Nanocarrier vaccines for SARS-CoV-2. <b>2021</b> , 171, 215-239		37
69	PRINCIPAIS ASPECTOS DO NOVO CORONAVÍRUS SARS-CoV-2: UMA AMPLA REVISÃO. <b>2021</b> , 25, 73-90		
68	SARS-CoV-2 Therapy: Old Drugs as New Interventions. <i>Coronaviruses</i> , <b>2021</b> , 2, 142-150	1.5	1
67	Dodging COVID-19 infection: low expression and localization of ACE2 and TMPRSS2 in multiple donor-derived lines of human umbilical cord-derived mesenchymal stem cells. <b>2021</b> , 19, 149		6
66	Discovery of Potential Inhibitors of SARS-CoV-2 (COVID-19) Main Protease (Mpro) from Nigella Sativa (Black Seed) by Molecular Docking Study. <i>Coronaviruses</i> , <b>2021</b> , 2, 384-402	1.5	8
65	Structure-based assortment of herbal analogues against spike protein to restrict COVID-19 entry through hACE2 receptor: An in-silico approach. <b>2021</b> , 64, 159-171		2
64	Managing drug shortages during a pandemic: tocilizumab and COVID-19. <b>2021</b> , 193, E771-E776		2
63	Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. <b>2021</b> , 151, 112106		3
62	The Pandemic as a Rupture that Follows Rules: Comparing Governance Responses in India, USA, Sweden and Norway. <i>Frontiers in Human Dynamics</i> , <b>2021</b> , 3,	0.7	1
61	Hydroxychloroquine Induced DRESS (Drug Rash with Eosinophilia and Systemic Symptoms Syndrome) Mimicking SARS-COV-2 Illness: A Case Report with Review. <i>Coronaviruses</i> , <b>2021</b> , 2, 521-526	1.5	
60	Hydroxychloroquine: Pharmacological, physicochemical aspects and activity enhancement through experimental formulations. <i>Journal of Drug Delivery Science and Technology</i> , <b>2021</b> , 63, 102512	4.5	0
59	COVID-19 Global Pandemic Fight by Drugs: A Mini-Review on Hope and Hype. <i>Mini-Reviews in Organic Chemistry</i> , <b>2021</b> , 18,	1.7	
58	Ayurveda botanicals in COVID-19 management: An in silico multi-target approach. <i>PLoS ONE</i> , <b>2021</b> , 16, e0248479	3.7	17
57	Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study. <i>PLoS ONE</i> , <b>2021</b> , 16, e0252388	3.7	2
56	COVID-19: Patient care after discharge from the Intensive Care Unit. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e14270	2.9	1

55	Using crowdsourced medicine to manage uncertainty on Reddit: The case of COVID-19 long-haulers. <i>Patient Education and Counseling</i> , <b>2021</b> ,	3.1	3
54	Systemic lupus erythematosus on social networking sites: Friends or foes?. <i>Lupus</i> , <b>2021</b> , 30, 1873-1878	2.6	
53	Individual health behaviours to combat the COVID-19 pandemic: lessons from HIV socio-behavioural science. <i>Journal of the International AIDS Society</i> , <b>2021</b> , 24, e25771	5.4	2
52	Hydroxychloroquine/chloroquine in patients with COVID-19 in Wuhan, China: a retrospective cohort study. <i>BMC Infectious Diseases</i> , <b>2021</b> , 21, 805	4	3
51	Can use of hydroxychloroquine and azithromycin as a treatment of COVID-19 affect aquatic wildlife? A study conducted with neotropical tadpole. <i>Science of the Total Environment</i> , <b>2021</b> , 780, 146553	10.2	4
50	No difference in biomarkers of ischemic heart injury and heart failure in patients with COVID-19 who received treatment with chloroquine phosphate and those who did not. <i>PLoS ONE</i> , <b>2021</b> , 16, e0256035	3.7	
49	Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: A meta-review of systematic reviews and an updated meta-analysis. <i>Travel Medicine and Infectious Disease</i> , <b>2021</b> , 43, 102135	8.4	4
48	Identification of potential therapeutic targets and mechanisms of COVID-19 through network analysis and screening of chemicals and herbal ingredients. <i>Briefings in Bioinformatics</i> , <b>2021</b> ,	13.4	2
47	Management of Future Outbreak Risks (Prevention, Control and Treatment). <i>EAI/Springer Innovations in Communication and Computing</i> , <b>2022</b> , 67-89	0.6	
46	The myocardial and neuronal infectivity of SARS-CoV-2 and detrimental outcomes. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2021</b> , 99, 1128-1136	2.4	
45	Environmental impacts of COVID-19 treatment: Toxicological evaluation of azithromycin and hydroxychloroquine in adult zebrafish. <i>Science of the Total Environment</i> , <b>2021</b> , 790, 148129	10.2	2
44	Repurposing the inhibitors of COVID-19 key proteins through molecular docking approach. <i>Process Biochemistry</i> , <b>2021</b> , 110, 216-222	4.8	3
43	Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications. <i>Environmental Science and Pollution Research</i> , <b>2021</b> , 28, 40431-40444	5.1	13
42	Radiation therapy for COVID-19 pneumopathy. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 147, 210-211	5.3	6
41	Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide. <i>Bioscience Reports</i> , <b>2020</b> , 40,	4.1	17
40	No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial.		48
39	Benefits and Risks of Chloroquine and Hydroxychloroquine in The Treatment of Viral Diseases: A Meta-Analysis of Placebo Randomized Controlled Trials.		1
38	Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South Korea.		7



37	Do medical interns feel prepared to work in the COVID-19 pandemic?. <i>Revista Da Associação Médica Brasileira</i> , <b>2020</b> , 66, 973-978	1.4	3
36	Risk of COVID-19 infection among lupus erythematosus patients and rheumatoid arthritis patients: a retrospective study in Hubei, China. <i>European Journal of Dermatology</i> , <b>2020</b> , 30, 751-753	0.8	3
35	Current Clinical Trials and Vaccine Development Strategies for Corona Virus Disease (COVID-19). <i>Journal of Pure and Applied Microbiology</i> , <b>2020</b> , 14, 979-988	0.9	1
34	Drug Repositioning for COVID-19. <i>Colombia Medica</i> , <b>2020</b> , 51, e4279	1.5	3
33	COVID-19 and sickle cell disease. <i>Haematologica</i> , <b>2020</b> , 105, 2501-2504	6.6	14
32	Neurosurgery and Neurology Practices during the Novel COVID-19 Pandemic: A Consensus Statement from India. <i>Neurology India</i> , <b>2020</b> , 68, 246-254	0.7	42
31	Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review. <i>Medical Gas Research</i> , <b>2020</b> , 10, 134-138	2.2	4
30	Wide Applications of Chloroquine Other Than Antimalarial. <i>Pharmacology &amp; Pharmacy</i> , <b>2020</b> , 11, 251-281	0.3	1
29	Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence. <i>European Journal of Rheumatology</i> , <b>2020</b> , 7, S110-S116	1.7	4
28	Conducting research in a pandemic: The power of social media. <i>European Journal of Rheumatology</i> , <b>2020</b> , 7, S85-S88	1.7	5
27	Ethical Considerations of Hydroxychloroquine During the COVID-19 Pandemic. <i>Journal of Contemporary Pharmacy Practice</i> , <b>2021</b> , 68, 7-8	0.1	
26	Coronavirus Disease 2019 (COVID-19): An Evidence Map of Medical Literature.		0
25	Chloroquine and hydroxychloroquine effectiveness in human subjects during coronavirus: a systematic review.		
24	An early assessment of the efficacy of medicines in the treatment of patients with COVID-19. <i>Russian Journal of Infection and Immunity</i> , <b>2020</b> , 10, 277-286	0.4	1
23	QT Interval Prolongation in Patients Treated for COVID-19.		
22	Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19. <i>Sudanese Journal of Paediatrics</i> , <b>2020</b> , 20, 4-9	0.6	1
21	Transcriptomic Signatures and Immunomodulatory Treatments for COVID-19 Patients. <i>SSRN Electronic Journal</i> ,	1	
20	Discovery of Potential Inhibitors of SARS-CoV-2 (COVID-19) Main Protease (Mpro) from Nigella Sativa (Black Seed) by Molecular Docking Study (Preprint).		

19	Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: a meta-review of systematic reviews and an updated meta-analysis.		1
18	The COVID-19 era: the view from Nigeria. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2021</b> , 114, 13-15	2.7	1
17	The COVID-19 war and the battles of rheumatologists. <b>2020</b> , 2, 41-42		
16	Automatic registration for UK trials.. <i>BMJ, The</i> , <b>2022</b> , 376, o41	5.9	1
15	Mechanism of Blood-Heart-Barrier Leakage: Implications for COVID-19 Induced Cardiovascular Injury.. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
14	Self-medication and the 'infodemic' during mandatory preventive isolation due to the COVID-19 pandemic.. <i>Therapeutic Advances in Drug Safety</i> , <b>2022</b> , 13, 20420986221072376	3.5	0
13	New In Silico Insights into the Application of (Hydroxy)Chloroquine with Macrolide Antibiotic Co-Crystals against the SARS-CoV-2 Virus. <i>Covid</i> , <b>2022</b> , 2, 230-243		0
12	Accelerating Drug Discovery and Development. <b>2022</b> , 385-420		
11	COVID-19 in patients with systemic lupus erythematosus: A systematic review.. <i>Lupus</i> , <b>2022</b> , 9612033221093502		
10	COVID-19 Myth Busters: Comparing knowledge and perceptions amongst the dental workforce at an institution in the Eastern Province, Saudi Arabia.. <i>PLoS ONE</i> , <b>2021</b> , 16, e0260698	3.7	0
9	Detecting Tweets Containing Cannabidiol-Related COVID-19 Misinformation Using Transformer Language Models and FDA Warning Letters (Preprint).		
8	Health care utilization and costs of systemic lupus erythematosus in the United States: A systematic review.. <i>Lupus</i> , <b>2022</b> , 9612033221088209	2.6	0
7	Microorganisms in Pathogenesis and Management of Systemic Lupus Erythematosus (SLE). <b>2022</b> , 507-551		
6	Analysis of hydroxychloroquine adverse events in COVID-19 patients reported throughout Iraqi pharmacovigilance center in VigiBase A study based on WHO database. 11, 923		
5	Detecting Tweets Containing Cannabidiol-Related COVID-19 Misinformation Using Transformer Language Models and FDA Warning Letters (Preprint).		0
4	In silico study to find a potent inhibitor, Vilazodone, to cure COVID-19 using molecular docking. <b>2022</b> ,		0
3	Going beyond fact-checking to fight health misinformation: A multi-level analysis of the Twitter response to health news stories. <b>2023</b> , 70, 102626		0
2	Quinoline analogue as a potential inhibitor of SARS-CoV-2 main protease: ADMET prediction, molecular docking and dynamics simulation analysis. <b>2023</b> , 14, 30-38		0

- 1 The immunomodulatory properties of low-level ionizing radiation as a potential treatment for COVID-19 life-threatening symptoms. **2023**, 28,

o